JP2008543878A5 - - Google Patents

Download PDF

Info

Publication number
JP2008543878A5
JP2008543878A5 JP2008517207A JP2008517207A JP2008543878A5 JP 2008543878 A5 JP2008543878 A5 JP 2008543878A5 JP 2008517207 A JP2008517207 A JP 2008517207A JP 2008517207 A JP2008517207 A JP 2008517207A JP 2008543878 A5 JP2008543878 A5 JP 2008543878A5
Authority
JP
Japan
Prior art keywords
peptide agent
use according
terminal
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008517207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008543878A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/023759 external-priority patent/WO2006138708A1/en
Publication of JP2008543878A publication Critical patent/JP2008543878A/ja
Publication of JP2008543878A5 publication Critical patent/JP2008543878A5/ja
Pending legal-status Critical Current

Links

JP2008517207A 2005-06-17 2006-06-19 凍結乾燥したかまたは凍結乾燥させることができる形態であるlkktetおよび/またはlkktntペプチド組成物 Pending JP2008543878A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69126105P 2005-06-17 2005-06-17
US77694706P 2006-02-28 2006-02-28
PCT/US2006/023759 WO2006138708A1 (en) 2005-06-17 2006-06-19 Lkktet and/or lkktnt peptide compositions which are lyophilized or in a form capable of being lyophilized

Publications (2)

Publication Number Publication Date
JP2008543878A JP2008543878A (ja) 2008-12-04
JP2008543878A5 true JP2008543878A5 (enExample) 2011-10-20

Family

ID=37570786

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008517207A Pending JP2008543878A (ja) 2005-06-17 2006-06-19 凍結乾燥したかまたは凍結乾燥させることができる形態であるlkktetおよび/またはlkktntペプチド組成物
JP2008517208A Withdrawn JP2008543879A (ja) 2005-06-17 2006-06-19 Lkktetおよび/またはlkktntペプチド組成物ならびに方法
JP2008517206A Pending JP2008543877A (ja) 2005-06-17 2006-06-19 Lkktetおよび/またはlkktnt組成物および組織の悪化、傷害または損傷を処置または予防するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2008517208A Withdrawn JP2008543879A (ja) 2005-06-17 2006-06-19 Lkktetおよび/またはlkktntペプチド組成物ならびに方法
JP2008517206A Pending JP2008543877A (ja) 2005-06-17 2006-06-19 Lkktetおよび/またはlkktnt組成物および組織の悪化、傷害または損傷を処置または予防するための方法

Country Status (11)

Country Link
US (8) US20090131313A1 (enExample)
EP (4) EP1904080A4 (enExample)
JP (3) JP2008543878A (enExample)
KR (3) KR20080018268A (enExample)
CN (1) CN105106931A (enExample)
AU (3) AU2006261155A1 (enExample)
CA (3) CA2612405A1 (enExample)
HK (1) HK1218248A1 (enExample)
IL (4) IL187522A0 (enExample)
MX (3) MX2007015956A (enExample)
WO (3) WO2006138707A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010010177A (es) * 2008-03-17 2012-08-23 Regenerx Biopharmaceuticals Fragmentos de beta timosina mejorada.
CN101297965B (zh) * 2008-06-16 2011-01-05 浙江省中医药研究院 胸腺肽β4在制备防治支气管哮喘药物中的应用
EP2485765A2 (en) 2009-10-09 2012-08-15 Board Of Regents The University Of Texas System Photokinetic ocular drug delivery methods and apparatus
WO2012126047A1 (en) * 2011-03-18 2012-09-27 Adistem Ltd Agent and method for treating pain and reducing inflammation
KR102038948B1 (ko) 2012-03-01 2019-11-26 퍼스트스트링 리서치 인코포레이티드 알파 코넥신 c-말단 (act) 펩타이드를 포함하는 국소 겔
EP2698162A1 (en) 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
TR201902755T4 (tr) * 2013-11-07 2019-03-21 Dr August Wolff Gmbh & Co Kg Arzneimittel Depolama kararliliğina sahi̇p li̇yofi̇li̇ze tri̇pepti̇t formülasyonlari.
JP6612247B2 (ja) 2014-03-12 2019-11-27 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン 眼の感染症および疾患を処置するための組成物および方法
US10406208B2 (en) 2014-10-22 2019-09-10 G-Treebnt Co., Ltd. Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
KR20170021667A (ko) 2015-08-18 2017-02-28 주식회사 지트리비앤티 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
US9867868B2 (en) * 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
KR102487614B1 (ko) 2015-10-06 2023-01-12 에이치엘비테라퓨틱스 주식회사 티모신 β4를 포함하는 안약의 제조방법
KR102488796B1 (ko) * 2016-07-18 2023-01-13 리젠트리 엘엘씨 안구 건조증 치료 방법
KR102115158B1 (ko) 2016-11-29 2020-05-26 주식회사 지트리파마슈티컬 티모신 베타 4 를 함유하는 제형
MX2019009759A (es) * 2017-02-21 2020-07-27 Tearsolutions Inc Composiciones de peptido estables.
KR102340750B1 (ko) 2017-03-03 2021-12-21 에이치엘비테라퓨틱스 주식회사 티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제
KR101910908B1 (ko) * 2017-06-14 2018-10-24 (주)휴온스 Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물
US10342824B2 (en) 2017-07-17 2019-07-09 Dr. Marlowe's Weight Loss Institute, P.L.L.C. Supplement for treating side effects of medications which cause metabolic acidosis
US20200353052A1 (en) * 2017-11-24 2020-11-12 G-Treebnt Co., Ltd. Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
MX2023004631A (es) 2020-10-22 2023-07-20 Xequel Bio Inc Formulaciones peptidicas y usos oftalmicos de las mismas.
CN119730839A (zh) * 2022-07-01 2025-03-28 缇尔索卢森公司 稳定的肽组合物及使用其治疗中/重度干眼相关的眼部症状的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US4906613A (en) 1985-11-05 1990-03-06 Schering Corporation Antiglaucoma compositions and methods
NZ235556A (en) 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
FR2647675B1 (fr) 1989-06-05 1994-05-20 Sanofi Utilisation d'un derive de la statine dans le traitement des affections oculaires
US5564345A (en) * 1993-05-11 1996-10-15 Park Ohio Industries Inc. Stackable table, table assembly, and tray and table combination
DK0639070T4 (da) * 1992-05-06 2010-12-13 Alcon Lab Inc Anvendelse af borat-polyolkomplekser til ophtalmiske præparater
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
WO1996003158A1 (en) 1994-07-22 1996-02-08 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
GB9806632D0 (en) 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
US20040131626A1 (en) * 2001-03-15 2004-07-08 Goldstein Allan L. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (tb4) analogues, isoforms and other derivatives
EP1591128A1 (en) * 1998-07-30 2005-11-02 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Thymosin beta 4 promotes wound repair
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
WO2002024234A2 (en) * 2000-09-20 2002-03-28 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
JP2005502672A (ja) * 2001-08-29 2005-01-27 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド サイモシンβ4、類似体、アイソフォームおよびその他の誘導体を用いて心筋障害の発生前、発生中または発生後に発生する炎症、損傷およびその他の変化を治癒または予防する方法
US20040005644A1 (en) * 2002-02-28 2004-01-08 Su Yan A. Method and composition for detection and treatment of breast cancer
AU2003278727A1 (en) * 2002-09-20 2004-04-08 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US20060263360A1 (en) 2003-03-31 2006-11-23 Regenerx Biopharmaceuticals, Inc. Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives
WO2004099768A1 (en) * 2003-05-05 2004-11-18 Regenerx Biopharmaceuticals, Inc. Method for detecting development of a physiological disorder in a subject
KR102632066B1 (ko) 2015-07-30 2024-02-02 가부시키가이샤 한도오따이 에네루기 켄큐쇼 발광 장치의 제작 방법, 발광 장치, 모듈, 및 전자 기기

Similar Documents

Publication Publication Date Title
JP2008543878A5 (enExample)
US11911447B2 (en) Peptide pharmaceuticals for insulin resistance
AU634954B2 (en) Treatment of diabetes mellitus
KR102255479B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 제약
US20200289653A1 (en) Improved peptide pharmaceuticals for insulin resistance
CN102292346B (zh) 肥胖的治疗
KR102542164B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 약제
CA2698582A1 (en) Peptide having an extending action for half-life of object peptide in plasma
KR20240128130A (ko) 펩티드 wkdeagkplvk를 포함하는 조성물
CN116322739A (zh) Glp-1r激动剂/fgf21融合蛋白
CN110300595A (zh) Pac1受体激动剂(maxcap)及其用途
CN103391786B (zh) 作为抗糖尿病肽的载脂蛋白a-iv
US20200172587A1 (en) Hydrochloride salts of c5a receptor agonist peptides
JP3260760B2 (ja) ヒルジンを含んでなる医薬組成物
CN116113639A (zh) 活性降低的glp-1r激动肽
JP3350604B2 (ja) ヒルジン含有医薬組成物
CN104592380A (zh) 一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用
WO2018188565A1 (zh) 用于治疗代谢系统疾病的多肽及其组合物
WO2017121764A1 (en) Pharmaceutical formulations for the treatment of diabetes
JP2017532292A (ja) ミリストイル化レプチン関連ペプチド及びその使用
WO2024234320A1 (zh) 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途
US20210171604A1 (en) Peptides for the treatment of type 2 diabetes